当前位置: X-MOL 学术Cardiovasc. Interv. Radiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Intra-Arterial Therapies for Liver Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
CardioVascular and Interventional Radiology ( IF 2.9 ) Pub Date : 2021-07-28 , DOI: 10.1007/s00270-021-02906-1
B M Aarts 1, 2 , F M Gómez Muñoz 1, 3 , H Wildiers 4 , V O Dezentjé 5 , T R Baetens 1 , W Schats 6 , M Lopez-Yurda 6 , R C Dresen 7 , B J de Wit-van der Veen 8 , C M Deroose 9 , G Maleux 7 , R G H Beets-Tan 1, 2 , E G Klompenhouwer 1
Affiliation  

PURPOSE Performing a systematic review and meta-analysis to assess the evidence of intra-arterial therapies in liver metastatic breast cancer (LMBC) patients. METHODS A systemic literature search was performed in PubMed, EMBASE, SCOPUS for studies regarding intra-arterial therapies in LMBC patients. Full text studies of LMBC patients (n ≥ 10) published between January 2010 and December 2020 were included when at least one outcome among response rate, adverse events or survival was available. Response rates were pooled using generalized linear mixed models. A weighted estimate of the population median overall survival (OS) was obtained under the assumption of exponentially distributed survival times. RESULTS A total of 26 studies (1266 patients) were included. Eleven articles reported on transarterial radioembolization (TARE), ten on transarterial chemoembolization (TACE) and four on chemo-infusion. One retrospective study compared TARE and TACE. Pooled response rates were 49% for TARE (95%CI 32-67%), 34% for TACE (95%CI 22-50%) and 19% for chemo-infusion (95%CI 14-25%). Pooled median survival was 9.2 months (range 6.1-35.4 months) for TARE, 17.8 months (range 4.6-47.0) for TACE and 7.9 months (range 7.0-14.2) for chemo-infusion. No comparison for OS was possible due to missing survival rates at specific time points (1 and 2 year OS) and the large heterogeneity. CONCLUSION Although results have to be interpreted with caution due to the large heterogeneity, the superior response rate of TARE and TACE compared to chemo-infusion suggests first choice of TARE or TACE in chemorefractory LMBC patients. Chemo-infusion could be considered in LMBC patients not suitable for TARE or TACE. LEVEL OF EVIDENCE 3a.

中文翻译:

肝转移性乳腺癌的动脉内治疗:系统评价和荟萃分析。

目的 进行系统评价和荟萃分析,以评估肝转移性乳腺癌 (LMBC) 患者动脉内治疗的证据。方法 在 PubMed、EMBASE、SCOPUS 中进行系统性文献检索,以研究有关 LMBC 患者动脉内治疗的研究。2010 年 1 月至 2020 年 12 月期间发表的 LMBC 患者(n ≥ 10)的全文研究被纳入,其中至少有反应率、不良事件或生存率中的一个结果可用。使用广义线性混合模型汇总响应率。在生存时间呈指数分布的假设下,获得了人口中位总生存期 (OS) 的加权估计。结果 共纳入 26 项研究(1266 名患者)。11 篇文章报道了经动脉放射栓塞 (TARE),十项关于经动脉化疗栓塞 (TACE),四项关于化学输注。一项回顾性研究比较了 TARE 和 TACE。TARE (95%CI 32-67%) 的汇总反应率为 49%,TACE (95%CI 22-50%) 为 34%,化疗输注为 19% (95%CI 14-25%)。TARE 的合并中位生存期为 9.2 个月(范围 6.1-35.4 个月),TACE 为 17.8 个月(范围 4.6-47.0),化疗输注为 7.9 个月(范围 7.0-14.2)。由于缺少特定时间点(1 年和 2 年 OS)的生存率和较大的异质性,无法比较 OS。结论 尽管由于异质性大,必须谨慎解释结果,但与化学输注相比,TARE 和 TACE 的优异反应率表明,对于化学难治性 LMBC 患者,首选 TARE 或 TACE。对于不适合 TARE 或 TACE 的 LMBC 患者,可以考虑化学输注。证据水平 3a。
更新日期:2021-07-28
down
wechat
bug